{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:51Z","timestamp":1790188311251,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,8]]},"DOI":"10.7759\/cureus.24829","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T18:02:37Z","timestamp":1652032957000},"source":"Crossref","is-referenced-by-count":7,"title":["Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Nabeel R","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi Vijaya","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arowa","family":"Abdelgadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abanti","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes C","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018, 67:123-33. 10.1002\/hep.29466","journal-title":"Hepatology"},{"key":"ref2","article-title":"Non-alcoholic fatty liver disease: diagnosis and management","volume":"88","author":"Wilkins T","year":"2013","unstructured":"Wilkins T, Tadkod A, Hepburn I, Schade RR. Non-alcoholic fatty liver disease: diagnosis and management. Am Fam Physician. 2013, 88:35-42.","journal-title":"Am Fam Physician"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0806-8","article-title":"Non-alcoholic fatty liver disease","volume":"15","author":"Neuschwander-Tetri BA","year":"2017","unstructured":"Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017, 15:45. 10.1186\/s12916-017-0806-8","journal-title":"BMC Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi CK","year":"2022","unstructured":"Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022, 126:154925. 10.1016\/j.metabol.2021.154925","journal-title":"Metabolism"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.343","article-title":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity","volume":"33","author":"Kwak MS","year":"2018","unstructured":"Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med. 2018, 33:64-74. 10.3904\/kjim.2017.343","journal-title":"Korean J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub AM","year":"2021","unstructured":"Majzoub AM, Nayfeh T, Barnard A, et al.. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021, 54:880-9. 10.1111\/apt.16583","journal-title":"Aliment Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome P","year":"2019","unstructured":"Newsome P, Francque S, Harrison S, et al.. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment Pharmacol Ther. 2019, 50:193-203. 10.1111\/apt.15316","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/8755122516687122","article-title":"Obeticholic acid: a Farnesoid X receptor agonist for Primary biliary cholangitis","volume":"33","author":"Smith SM","year":"2017","unstructured":"Smith SM, Pegram AH. Obeticholic acid: a Farnesoid X receptor agonist for Primary biliary cholangitis. J Pharm Technol. 2017, 33:66-71. 10.1177\/8755122516687122","journal-title":"J Pharm Technol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101675","article-title":"Efficacy and safety of obeticholic acid in liver disease-a systematic review and meta-analysis","volume":"45","author":"Kulkarni AV","year":"2021","unstructured":"Kulkarni AV, Tevethia HV, Arab JP, et al.. Efficacy and safety of obeticholic acid in liver disease-a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021, 45:101675. 10.1016\/j.clinre.2021.101675","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021, 11:73. 10.3390\/metabo11020073","journal-title":"Metabolites"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1131","article-title":"Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment","volume":"58","author":"Baekdal TA","year":"2018","unstructured":"Baekdal TA, Thomsen M, Kup\u010dov\u00e1 V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018, 58:1314-23. 10.1002\/jcph.1131","journal-title":"J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint A","year":"2021","unstructured":"Flint A, Andersen G, Hockings P, et al.. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021, 54:1150-61. 10.1111\/apt.16608","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri BA","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al.. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015, 385:956-65. 10.1016\/S0140-6736(14)61933-4","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al.. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 2019, 394:2184-96. 10.1016\/S0140-6736(19)33041-7","journal-title":"The Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2784537","article-title":"Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis","volume":"2018","author":"Li B","year":"2018","unstructured":"Li B, Zhang C, Zhan YT. Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol. 2018, 2018:2784537. 10.1155\/2018\/2784537","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990344","article-title":"Pathophysiology of NASH: perspectives for a targeted treatment","volume":"19","author":"Marra F","year":"2013","unstructured":"Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013, 19:5250-69. 10.2174\/13816128113199990344","journal-title":"Curr Pharm Des"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang XC","year":"2014","unstructured":"Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol. 2014, 20:14821-30. 10.3748\/wjg.v20.i40.14821","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier JJ","year":"2021","unstructured":"Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021, 12:645617. 10.3389\/fendo.2021.645617","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid-a new therapy in PBC and NASH","volume":"133","author":"Chapman RW","year":"2020","unstructured":"Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH. Br Med Bull. 2020, 133:95-104. 10.1093\/bmb\/ldaa006","journal-title":"Br Med Bull"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040104","article-title":"Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli L","year":"2018","unstructured":"Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals (Basel). 2018, 11:104. 10.3390\/ph11040104","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","article-title":"Obeticholic acid","author":"Novotny K","year":"2021","unstructured":"Novotny K, Hapshy V, Nguyen H. Obeticholic acid. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1079","article-title":"Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic","volume":"1","author":"Filozof C","year":"2017","unstructured":"Filozof C, Chow SC, Dimick-Santos L, Chen YF, Williams RN, Goldstein BJ, Sanyal A. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol Commun. 2017, 1:577-85. 10.1002\/hep4.1079","journal-title":"Hepatol Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi ZM","year":"2018","unstructured":"Younossi ZM, Loomba R, Anstee QM, et al.. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018, 68:349-60. 10.1002\/hep.29721","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-48559-3.00009-9","article-title":"Chapter 9: Obesity and non-alcoholic fatty liver disease","author":"de Alwis NMW","year":"2018","unstructured":"de Alwis NMW. Chapter 9: Obesity and non-alcoholic fatty liver disease. Practical Guide to Obesity Medicine. Weaver JU (ed): Elsevier, St. Louis, MO; 2018. 89-97. 10.1016\/B978-0-323-48559-3.00009-9"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.10.008","article-title":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease","volume":"20","author":"Hannah WN Jr","year":"2016","unstructured":"Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016, 20:339-50. 10.1016\/j.cld.2015.10.008","journal-title":"Clin Liver Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/87.5.1141","article-title":"Effect of a dietary-induced weight loss on liver enzymes in obese subjects","volume":"87","author":"Gasteyger C","year":"2008","unstructured":"Gasteyger C, Larsen TM, Vercruysse F, Astrup A. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr. 2008, 87:1141-7. 10.1093\/ajcn\/87.5.1141","journal-title":"Am J Clin Nutr"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal Farnesoid X Receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner M","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, et al.. The nonsteroidal Farnesoid X Receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019, 70:788-801. 10.1002\/hep.30509","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros PJ","year":"2019","unstructured":"Pockros PJ, Fuchs M, Freilich B, et al.. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019, 39:2082-93. 10.1111\/liv.14209","journal-title":"Liver Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos AF","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020, 12:60. 10.1186\/s13098-020-00570-y","journal-title":"Diabetol Metab Syndr"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2014.00037","article-title":"Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy","volume":"3","author":"Zhang QQ","year":"2015","unstructured":"Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015, 3:78-84. 10.14218\/JCTH.2014.00037","journal-title":"J Clin Transl Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84266-comparing-the-efficacy-and-safety-of-obeticholic-acid-and-semaglutide-in-patients-with-non-alcoholic-fatty-liver-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:02Z","timestamp":1707507722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84266-comparing-the-efficacy-and-safety-of-obeticholic-acid-and-semaglutide-in-patients-with-non-alcoholic-fatty-liver-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.24829","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,8]]}}}